Evidence map›Paper›PMID 33324425›Full record

ReviewFrontiers in immunology2020

MIF-Dependent Control of Tumor Immunity.

Jordan T Noe, Robert A Mitchell

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 192 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Integrative single-cell analysis revealsFrontiers in immunology · 2026
    Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jordan T NoeDepartment of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, United States.
Robert A MitchellDepartment of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, United States.
University of Louisville · US

Funding

Small molecule targeting of MIF as a novel melanoma therapeuticR01CA186661 · NCI · UNIVERSITY OF LOUISVILLE · PI MITCHELL, ROBERT A · 2014 to 2018
$1.6M
The role of MIF in mitochondrial metabolism and M2-TAM polarizationF30CA232550 · NCI · UNIVERSITY OF LOUISVILLE · PI NOE, JORDAN T · 2019 to 2022
$166k
NCI NIH HHS F30 CA232550NCI NIH HHS R01 CA186661
6 · The paper itself

Abstract

Initially identified as a T lymphocyte-elicited inhibitor of macrophage motility, macrophage migration inhibitory factor (MIF) has since been found to be expressed by nearly every immune cell type examined and overexpressed in most solid and hematogenous malignant cancers. It is localized to both extracellular and intracellular compartments and physically interacts with more than a dozen different cell surface and intracellular proteins. Although classically associated with and characterized as a mediator of pro-inflammatory innate immune responses, more recent studies demonstrate that, in malignant disease settings, MIF contributes to anti-inflammatory, immune evasive, and immune tolerant phenotypes in both innate and adaptive immune cell types. This review will summarize the studies describing MIF in tumor-specific innate and adaptive immune responses and attempt to reconcile these various pleiotropic functions in normal physiology.

Indexed as

Tumor EscapeAdaptive ImmunityAnimalsCell CommunicationHumansImmunity, InnateImmunotherapyIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsNeoplasmsSignal TransductionTumor MicroenvironmentIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humancytokinesdendritic cellsimmune evasionimmunotherapylymphocytesmacrophagesmigration inhibitory factortumor immunity

Identifiers

PMID33324425
PMCPMC7724107
OpenAlexW3108823610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.